摘要
【摘要】 目的 对肠杆菌科细菌 ESBLs和 AmpC酶检测结果与耐药性情况进行分析探讨，为今后的临床合理用药提供可靠的参考依据。方法 抽取 2018年 1月至 2020年 3月间我院患者标本培养的肠杆菌 236株，分别采取用双纸片氯唑西林增效试验和双纸片确诊试验对 AmpC酶与 ESBLs表型进行检测，并展开相应的药敏试验。结果 本组 236株菌株中检出 AmpC酶菌 102株，检出 ESBLs菌 120株；单产 AmpC酶菌、单产 AmpC酶菌和产 ESBLs和 AmpC酶菌对氨曲南、头孢噻肟的耐药率较非产 AmpC酶菌高（ P<0.05）；所有肠杆菌对青霉素具有较高的耐药率。结论 ESBLs和 AmpC酶为肠杆菌科细菌耐药的主要因素，临床应给予关注。
【关键词】肠杆菌； ESBLs； AmpC酶；耐药性
[Abstract] Objective To analyze the detection results of ESBLs and AmpC enzymes and drug resistance of Enterobacteriaceae, so as to provide reliable reference for clinical rational drug use in the future. Methods 236 Enterobacteriaceae strains were collected from patients in our hospital from January 2018 to March 2020. AmpC enzyme and ESBLs phenotype were detected by double disk cloxacillin synergistic test and double disk confirmatory test, and the corresponding drug sensitivity test was carried out. Results 102 strains of AmpC enzyme producing bacteria and 120 strains of ESBLs bacteria were detected in this group of 236 strains. The resistance rates of AmpC enzyme producing bacteria, AmpC enzyme producing bacteria and ESBLs and AmpC enzyme producing strains to aztreonam and cefotaxime were higher than those of non AmpC producing strains (P < 0.05); all Enterobacteriaceae had high resistance rate to penicillin. Conclusion ESBLs and AmpC enzyme are the main factors of drug resistance of Enterobacteriaceae, which should be paid attention to in clinic.
出版日期
2020年09月14日（中国期刊网平台首次上网日期，不代表论文的发表时间）
